EXPERIMENTAL SUBSTANTIATION OF CARBOXYTHETERAPY IN THE TREATMENT OF PAIN SYNDROME
Almost every person can felt the pain syndrome; it has different mechanisms of formation, which must be taken into account when determining the principles of treatment. The causes of pain are inflammation, ischemia, hypoxia, oxidative stress, etc. Non-steroidal anti-inflammatory drugs are the most common painkillers, but the problem of expected efficiency and their potential risks is not fully resolved despite their huge assortment. Therefore, the search for alternative effective and safer methods of anelgesia, one of which is carboxytherapy (treatment of CO2). Carbon dioxide (CO2) is an inalienable component of the metabolism and pacemaker of the respiratory processes. The objective of the work was to study the analgesic effect of carboxytherapy (subcutaneous injections of carbon dioxide). For this purpose, we used a combined model of hyperalgesia (with a central component): carrageenan inflammation in combination with a modification of the tail immersion test. The animals (40 rats) used in the experiment were divided into five groups: I – control pathology; II – rats receiving injections of diclofenac sodium comparator at a dose of 8 mg / kg; III – animals that were subcutaneously injected with CO2 into the hind paw at a dose of 0.5 ml; IV – animals that were injected with CO2 into the hind paw at a dose of 1 ml; V – rats that received 4 mg/kg of diclofenac in combination with subcutaneous injection of CO2 into the hind paw at a dose of 1 ml. In the experiment on rats was found that subcutaneous injections of carboxytherapy at a dose of 0.5 ml and 1 ml have analgesic properties (at the level of 18.9 and 31.1 %), but the most perspective method is the complex purpose of analgesics (diclofenac sodium at a dose of 4 mg/kg) and injection of carboxytherapy (at a dose of 1 ml), which helps to reduce the degree of analgesia by 38.7 %, which correlates with the action of diclofenac sodium (at a dose of 8 mg/kg). Thus, the inclusion of carboxytherapy in conventional therapies will enhance the analgesic effect of a traditional drug and improve the safety profile of the latter.
Barinov A. N., Ahmedzhanova L. T., Mahinov K. A. Bol' i starenie – osobennosti lecheniya pozhilyh pacientov // Zdorov’ya Ukraїni. – 2017. – № 1. – Р. 38–40.
Drogovoz S. M., Shtrygol' S. Yu., Kononenko A. V. i dr. Mekhanizm dejstviya karboksiterapii // Farmakologiya i lekarstvennaya toksikologiya. – 2016. – № 6. – Р. 83–87.
Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv. Ch. 1 / Pod red. A. N. Mironova. – M.: Grif i K., 2012. – 944 р.
Goldberg D. S., McGee S. J. Pain as a global public health priority // Bio. Med. Central. – 2011. – Vol. 770, N 11. – Р. 1–5.
Hall E. L., Driver I. D., Croal P. L. et al. The effect of hypercapnia on resting and stimulus induced MEG signals // Neuro Image. – 2011. – Vol. 58, N. 4. – P. 1034–1043.
Li A. M., Quan Y., Guo Y. P. et al. Effects of therapeutic hypercapnia on inﬂammation and apoptosis after hepatic ischemia-reperfusion injury in rats // Chin. Med. J. (Engl). – 2010. – Vol. 123. – Р. 2254–2258.
Macfarlane G. J., Kronisch C., Dean L. E. et al. EULAR revised recommendations for the management of ﬁbromyalgia // Ann. Rheum. Dis. – 2017. – Vol. 76, N. 2. – Р. 318–328.
Taylor Т. C., Cummins Р. E. Regulation of gene expression by carbon // J. Physiol. – 2011. – Vol. 589, N. 4. – P. 797–803.
The Preventable Pain Pandemic. – http://www.who.int/ncds/management/palliative-care/preventable_pain/en/
Abstract views: 85 PDF Downloads: 52
This work is licensed under a Creative Commons Attribution 4.0 International License.